I couldn't find anything saying humans produced significant quantities of alpha-methyldopamine from (meth)amphetamine either, though I'm not quite sure what significance this has to your assertion that its majorly responsible for the inter-species difference in neurotoxicity. It's fairly benign in rats, which is where a lot of the inter-species differences claims come from
http://www.ncbi.nlm.nih.gov/pubmed/1860050. Now I might be missing a study that shows it destroys monkeys, but I don't follow your logic saying that metabolism of (meth)amphetamine into 3,4-dihydroxyl products is a major determinant of inter species vulnerability. MDMA we can both agree is going to have a lot of species variance with metabolism and is likely going to be effected by this, but I still don't understand exactly what you're getting at here.
AAAH is the only enzyme in our metabolic repertoire with the capacity to 3-hydroxylate
these types of compounds (endogenous/exogenous PEA's). Human AAAH doesn't act on amph. This means AMDopa isn't a metabolite; that in turn implies its quinones and GSH conjugates are not metabolites. That's all I'm asserting here.
This link goes over neurotoxicity research of AMDopa & its metabolites.
I didn't mean to suggest that this is
the reason for the differences seen in rats vs humans as much as
a possible and "reasonable explanation" for it. Metabolites may have nothing to do with interspecies variations in toxicity at all - it could come entirely from pharmacodynamic differences.
Stimulant and stress induced arrhythmias and cardiomyopathies are commonly acknowledged adverse effects, I think the author is just cherry picked data to show that it can happen at therapeutic doses. Increased cortisol + the handful of other stress response hormones + vasoconstriction/hypertension + increased cardiac work load= occasional cardiac issues. I'm willing to bet that a substantial number of these cases had undiagnosed cardiac conduction issues or other risk factors. What a researcher can rant about "risk of severe cardiac events" the FDA will pretty much reply "Do not use if you have... If you experience... Call your doctor right away". Shitty evidence is shitty, but its nothing too out of the blue as far as I can see.
I agree with your premise and conclusion provided it's a single case. When I read a paper and think "WTF?" in several sections though, there's a problem. I'd let this section slide if the rest of the paper were written in a neutral, balanced point of view. Unfortunately, it's not.
I think its pretty well accepted that most if not all of (meth)amphetamine's neurotoxic actions stem from indirect damage. The issue I'm arguing is that we don't have a good measure for when amphetamine neurotoxicity begins in humans, we can all agree if its used responsibly and only at theraputic doses the damage is likely minimal. However, that doesn't mean harm reduction strategies aren't valid.
If you could detail exactly how (meth)amphetamine produces toxic metabolites in other primates or rodents but not humans I'd be very interested in hearing it! I don't mean to seem like I'm ragging on you, but I'd really like to see what you're getting at. Personally I'm more in the camp that differences in TAAR affinity or differences in responses to ROS are likely to be responsible for the noted inter species differences.
There is a large amount of clinical evidence that meth is neurotoxic in humans. There's two reviews out there asserting that sigma receptors play an important role in mediating its neurotoxic effects. (I already linked these)
There's a large amount of clinical evidence that amphetamine (permanently) restores/improves areas of brain function and structural abnormalities in those with ADHD.*** Another review I cited earlier stated that there's increased transporter availability seen in those who use amphetamine at therapeutic doses (this is the reverse case of neurotoxicity). So, in a nutshell, if there's some neurotoxic component to amphetamine when used at therapeutic doses, it's a triviality and not a cause for concern because its effect don't manifest clinically in humans.
So, I haven't been trying to argue that it's not neurotoxic. These papers have already shown that it's not, and even further provided evidence of it being a neurogenerative or neuroprotective compound (depends upon what causes the reductions in size for people with ADHD). Since these are reviews and meta-analyses of human data, this is high quality clinical evidence supporting these points. Everything else is just me been postulating why we see differences between species/compounds.
*** I'm too lazy to remove the wikitext. Just pull the "pmid=" value and search pubmed with it.
<ref name="Neuroplasticity 1">{{cite journal |author=Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K |title=Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects |journal=JAMA Psychiatry |volume=70 |issue=2 |pages=185–198 |date=February 2013 |pmid=
23247506 |doi=10.1001/jamapsychiatry.2013.277 |url=}}</ref>
<ref name="Neuroplasticity 2">{{cite journal |author=Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J |title=Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies |journal=J. Clin. Psychiatry |volume=74 |issue=9 |pages=902–917 |date=September 2013 |pmid=
24107764 |doi=10.4088/JCP.12r08287 |url= |pmc=3801446}}</ref>
<ref name="Neuroplasticity 3">{{cite journal | title=Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. | journal=Acta psychiatrica Scand. | date=February 2012 | volume=125 | issue=2 | pages=114–126 | pmid=
22118249 | author=Frodl T, Skokauskas N | quote=Basal ganglia regions like the right globus pallidus, the right putamen, and the nucleus caudatus are structurally affected in children with ADHD. These changes and alterations in limbic regions like ACC and amygdala are more pronounced in non-treated populations and seem to diminish over time from child to adulthood. Treatment seems to have positive effects on brain structure.}}</ref>